We care about your privacy. Read about your rights and how we protect your data. Get Details
HIV Research Lab


Over the years, we have partnered and continue to work closely with the National Institutes of Health-funded DC CFAR, MedStar Washington Hospital Center and George Washington University.

Special Immunology Services is excited to announce our partnership with Merck & Co. in an upcoming trial: A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine/Islatravir in Pediatric Participants with HIV-1 Infection who are Virologically Suppressed or Treatment-Naïve, are Less Than 18 Years of Age, and Weigh Greater Than or Equal to 35 kg. Approximate trial duration will be 96 weeks. Trial initiation will begin early 2021.